On November 13, 2026, Annovis Bio, Inc. announced its financial results for the third quarter ended September 30, 2026. This update is significant as it marks a critical phase for the company in its ongoing clinical trials for neurodegenerative diseases, particularly Alzheimer's and Parkinson's diseases.

During the quarter, Annovis reported a shift in focus from patient enrollment to executing trials and preparing for the first data readout. The company is anticipating a last patient visit for its Phase 3 DUET-AD study by December 31, 2026, with data expected to be available in March 2027. This timeline is crucial as it will inform the company’s next steps, including a potential New Drug Application (NDA).

Background

Annovis Bio, Inc., incorporated in Delaware, operates in the pharmaceutical preparations sector (SIC: 2834). The company is publicly traded on the New York Stock Exchange under the ticker symbol ANVS. Annovis specializes in developing treatments for neurodegenerative diseases, focusing on its investigational oral therapy, buntanetap.

What the Filing Says

The company's recent SEC filing indicates that it raised $21 million in gross proceeds through an underwritten public offering. This funding is expected to support operations through the upcoming data readout from the DUET-AD trial. The filing states, "We now have dates set for last patient, last visit of the 6-month treatment period and for database lock, as well as financing in place to carry us through topline results in March 2027," said Maria Maccecchini, President and CEO of Annovis.

Impact

This financial update and the upcoming clinical milestones may have significant implications for Annovis and its stakeholders, including investors and patients involved in the trials. The anticipated data readout could impact the company's market position and its ability to secure regulatory approval for its therapies. Additionally, this news may influence competitors in the pharmaceutical preparations sector, particularly those developing treatments for similar conditions.

What's Next

The company is preparing for the last patient visit in its DUET-AD study, with a database lock scheduled for February 8, 2027, and data readout expected in March 2027. Further filings may follow as the company approaches these critical milestones.